πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 89 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9752147

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9752152

Organic compositions to treat beta-ENaC-related diseases

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9745585

RNAi-mediated inhibition of histamine receptor H1-related conditions

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9562230

Transferrin/transferrin receptor-mediated siRNA delivery

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9550994

RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9540643

Organic compositions to treat HSF1-related diseases

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9526799

Low density lipoprotein receptor-mediated siRNA delivery

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9526796

Peptide-based in vivo siRNA delivery system

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9487556

Polyconjugates for delivery of RNAi triggers to tumor cells in vivo

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9476052

RNAi inhibition of alpha-ENaC expression

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9476047

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9474804

Poly(vinyl ester) polymers for in vivo nucleic acid delivery

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9452221

Poly(acrylate) polymers for in vivo nucleic acid delivery

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9453220

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9447419

RNAi-mediated inhibition of tumor necrosis factor Ξ±-related conditions

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9422556

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesi

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9376683

Organic compositions to treat beta-ENaC-related diseases

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted